The LiquidBiopsy™ instrument combined with the Ion Chef™ system and the Ion S5™ sequencers provide a seamless, end-to-end workflow for liquid biopsy cancer research. Learn how Cynvenio was able to scale up sample throughput using the Ion S5 sequencer.
Luca Quagliata, MD, of University Hospital, Basel, Switzerland discusses his use of the LiquidBiopsy platform and workflow in his research.
André de Fusco and Dr. Paul Dempsey (CEO and CSO of Cynvenio Biosystems Inc.) share their perspective on the need to simultaneously isolate cfDNA and circulating tumor cells (CTCs) from the same sample.
From the AACR 2015 exhibit floor, Vidya Venkatesh of Thermo Fisher Scientific shares the advantages of LiquidBiopsy system and workflow. From collection and stabilization to excellent recovery and downstream analysis this system isolates both cell-free DNA (cfDNA) and circulating tumor cells (CTCs) from a single whole-blood sample.
Jason Johnson of Thermo Fisher Scientific talks about finding circulating tumor cells with as few as 20 cells with the LiquidBiopsy Platform.
LiquidBiopsy Platform Overview
Dr. Strauss, Cynvenio's Director of Molecular Biology, discusses his work in using the Cynvenio Biosystems proprietary circulating tumor cell (CTC) isolation method, to develop a CTC DNA SNV sequencing platform.